Correlations between dosimetry and imaging in patients with neuroendocrine tumour treated with 177Lu-DOTATATE

#4631

Introduction: Tumour dose may be an important predictor of clinical response, but estimation of a clinically relevant tumour-absorbed dose without high risk of toxicity is challenging.

Aim(s): Our aim was to analyse the mean absorbed dose to the target lesions and its correlation with 68Ga-DOTATOC PET/CT changes parameters.

Materials and methods: This prospective study evaluated 52 lesions in 12 patients (5 women), mean age 63.4 ±10.4 treated with 7,2 (±0.3) GBq on 4 occasions (3 patients were retreatment). Carcinoid tumours of the foregut the most tumour type. For each patient, dosimetry was performed in the first and fourth cycle of the treatment to compute the mean absorbed doses at the target lesions. Target lesions was selected according to RECIST 1.1 criteria. For the dosimetry three SPECT-CT were acquired after treatment according with MIRD Pamphlet. Images were imported to specific software (MIM Software v7.3). Lesions that are not visible in CT were segmented with the same volume as previous 68Ga-DOTATOC PET/CT using a gradient based method (PETEdge plus tool) and specific workflow was followed.

Conference:

Presenting Author: Gomez Sanchez D

Authors: Gomez Sanchez D, Ribelles M, Fernandez Iglesias A, Paruta Araez L, Mata E,

Keywords: dosimetry, 177Lu-DOTATATE,